Eculizumab Substantially Reduces Myasthenia Gravis Events
(MedPage Today) -- PHOENIX – Generalized myasthenia gravis patients had dramatically lower incidence of flares and crises after starting on the complement component 5 inhibitor eculizumab (Soliris), data from a real-world registry showed... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - November 2, 2023 Category: Neurology Source Type: news
Lambert-Eaton Myasthenic Syndrome Underdiagnosed Alongside SCLC in the U.S.
(MedPage Today) -- PHOENIX -- While Lambert-Eaton myasthenic syndrome (LEMS) is known to be associated with small cell lung cancer (SCLC), researchers here suggested the autoimmune disorder is underdiagnosed in the U.S.
Using claims from a large... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 2, 2023 Category: Hematology Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
This study is ongoing.Study 301 (EMBARK), a Phase 3 global, randomised, double-blinded and placebo-controlled study of Elevidys in ambulatory Duchenne patients aged 4-<8 years old.The ENVOL trial (Study 302) a Phase 2 study in children with Duchenne. The study aims to enrol 21 participants who are under 4 years of age, including newborns. Not yet started.The ENVISION trial (Study 303), a Phase 3 study in older ambulatory/non-ambulatory patients which is now recruiting.The EXPEDITION long-term (5 year) follow up study (Study 305) of participants who have received Elevidys in a previous clinical study, which is not yet re...
Source: Roche Media News - October 31, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces EMBARK trial in Duchenne muscular dystrophy (DMD) did not reach primary endpoint, but shows positive efficacy outcomes on all timed functional key endpoints
This study is ongoing.Study 301 (EMBARK), a Phase 3 global, randomised, double-blinded and placebo-controlled study of Elevidys in ambulatory Duchenne patients aged 4-<8 years old.The ENVOL trial (Study 302) a Phase 2 study in children with Duchenne. The study aims to enrol 21 participants who are under 4 years of age, including newborns. Not yet started.The ENVISION trial (Study 303), a Phase 3 study in older ambulatory/non-ambulatory patients which is now recruiting.The EXPEDITION long-term (5 year) follow up study (Study 305) of participants who have received Elevidys in a previous clinical study, which is not yet re...
Source: Roche Investor Update - October 31, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves Zilbrysq for Generalized Myasthenia Gravis
TUESDAY, Oct. 24, 2023 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zilbrysq (zilucoplan) for the treatment of adults with generalized myasthenia gravis.Zilbrysq is a targeted... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 24, 2023 Category: Pharmaceuticals Source Type: news
Episode 6: Managing Myasthenia Gravis in Primary Care: Best Practices Episode 6: Managing Myasthenia Gravis in Primary Care: Best Practices
Drs Nicholas Silvestri and Michael Hehir discuss best practices for primary care physicians who see patients with myasthenia gravis.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 24, 2023 Category: Consumer Health News Tags: Neurology & Neurosurgery InDiscussion Source Type: news
FDA Approves New Drug for Generalized Myasthenia Gravis FDA Approves New Drug for Generalized Myasthenia Gravis
Zilucoplan is the first once-daily, subcutaneous, self-administered, targeted C5 complement inhibitor for adults with gMG who are AChR antibody positive.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - October 18, 2023 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
FDA Approves Zilbrysq (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis
ATLANTA, Oct. 17, 2023 /PRNewswire/ -- UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that Zilbrysq® (zilucoplan) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 17, 2023 Category: Drugs & Pharmacology Source Type: news
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitorfenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MSLonger-term safety data and late-breaking efficacy data from Phase III trial of ENSPRYNG (satralizumab) inneurom...
Source: Roche Media News - October 2, 2023 Category: Pharmaceuticals Source Type: news
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitorfenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MSLonger-term safety data and late-breaking efficacy data from Phase III trial of ENSPRYNG (satralizumab) inneurom...
Source: Roche Investor Update - October 2, 2023 Category: Pharmaceuticals Source Type: news
Episode 5: Myasthenia Gravis: Exercise and Lifestyle Considerations Episode 5: Myasthenia Gravis: Exercise and Lifestyle Considerations
Drs Nicholas Silvestri and Kelly Gwathmey discuss how exercise and other modifiable lifestyle factors can influence how patients experience the burden of myasthenia gravis.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 21, 2023 Category: Consumer Health News Tags: Neurology & Neurosurgery InDiscussion Source Type: news
Episode 4: Myasthenia Gravis: Who Really Benefits From Thymectomy? Episode 4: Myasthenia Gravis: Who Really Benefits From Thymectomy?
Drs Nicholas Silvestri and Gil Wolfe get right to the point about when and why thymectomy may be considered as an evidence-based option for treatment of myasthenia gravis.Medscape (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 23, 2023 Category: Surgery Tags: Neurology & Neurosurgery InDiscussion Source Type: news
Doctors have long considered the thymus expendable. But could removing it be fatal?
The thymus, a butterfly-shaped organ that sits between our collarbones, has never seemed like a particularly useful appendage—at least in adults. During early childhood, it provides a place for T cells (the T stands for thymus) to mature into immune cells that attack invaders. But during adolescence the organ begins to shrink and mostly stops producing these cells. By adulthood, it’s assumed to be so useless that cardiac surgeons will occasionally remove it just to get easier access to the heart.
But researchers have recently started to question that assumption, and a study published today in
The New England...
Source: ScienceNOW - August 2, 2023 Category: Science Source Type: news
Episode 3: Tools for More Personalized Myasthenia Gravis Care Episode 3: Tools for More Personalized Myasthenia Gravis Care
Drs Nicholas Silvestri and James ' Chip ' Howard, Jr, discuss newer and novel myasthenia gravis tools to personalize treatment, including complement inhibitors, FcRn antagonists, biomarkers, and more.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 25, 2023 Category: Consumer Health News Tags: Neurology & Neurosurgery InDiscussion Source Type: news
Myasthenia Gravis: What Remission Looks Like
Treatment for myasthenia gravis can help manage your symptoms. An expert shares his perspective on how to get to remission with MG. (Source: WebMD Health)
Source: WebMD Health - July 17, 2023 Category: Consumer Health News Source Type: news
